Clinical Data
The clinical characteristics of the 47 patients grouped by major HLA-DQw status are shown on Tables 1, 2, and 3. DQwl-positive subjects included the phenotypes, DQwl/DQw-, DQwl/DQw2, and DQwl/DQw3. DQwl-negative subjects included the phenotypes DQw2/DQw-, DQw3/DQw-, and DQw2/ DQw3. Similar subclassifications were made for the presence of DQw2 and DQw3 alleles. There were no significant differences in age, race, and sex distribution, duration of disease, or functional class among patients with different DQw alleles. Laboratory data and clinical measures of disease activity were also not statistically different, except for a lower geometric mean titer of rheumatoid factor in DQwl-positive patients (p<0.05) and a lower frequency of keratoconjunctivitis sicca in DQw2-positive patients (p<0.05). buy glucophage

The known linkage dysequilibrium of HLA-DR4 and DQW338 was observed in these patients; 24 of the 30 DQw3-positive patients had DR4, compared to none of the 17 DQw3-negative patients. The history of respiratory symptoms and pulmonary disease obtained by questionnaire failed to demonstrate any significant differences between major DQw groups in the presence of cough or production of sputum (or both), episodes of acute bronchitis, presence of chronic bronchitis, history of childhood or adult pneumonia, wheezing, dyspnea, history of emphysema, or significant occupational exposure. Likewise, there was no significant difference in pack-years when smokers were compared by major DQw subgroups. There was no difference in pulmonary function between subjects who had received penicillamine and those who had received gold therapy in the past.
The chest roentgenograms were classified as normal in 31 patients. Increased interstitial markings were present in 13 patients, with severe fibrosis and honeycombing in one subject. Hyperinflation was noted in seven subjects, and pleural thickening or costo-phrenic angle blunting was seen in four. There was no association of DQ phenotype with any specific chest roentgenographic abnormality.
Table 1—Demographic Characteristics of Patients with Rheumatoid Arthritis according to HLA-DQ

Group No. of Patients Age, yr* Race(W/B) Sex(F/M) Duration of Disease, yr* FunctionalClass*
DQ1 positive 30 54.2± 12.1 28/2 21/9 6.5±5.4t 2.2±0.4
DQ1 negative 17 57.7± 8.8 14/3 12/5 4.1 ±2.8t 2.1 ±0.2
DQ2 positive 16 53.1 ±10.5 14/2 11/5 5.9±5.8 2.1±0.3
DQ2 negative 31 56.7± 11.3 28/3 22/9 5.5±4.2 2.1 ±0.3
DQ3 positive 30 57.1 ±10.3 27/3 21/9 4.9±4.1 2.1 ±0.3
DQ3 negative 17 52.6 ±12.2 15/2 12/5 6.9±5.5 2.1±0.3

Table 2—Clinical Parameters according to HLA-DQ

Group No. of Patients No. of Painful Joints* No. of Swollen Joints* Stiff,h* Pain(0-10)* No.with

KCSt

HLA-DR4Status
DQ1 positive 30 19.9± 14.7 17.0±7.6 1.5± 1.2 4.7± 1.5 8/28 13/30
DQ1 negative 17 18.3± 12.2 17.5±9.1 1.4± 1.1 4.3± 1.1 2/15 11/17
DQ2 positive 16 19.6 ±15.1 17.0±9.9 1.5± 1.2 4.6±0.07 0/15$ 2/16§
DQ2 negative 31 19.1 ±13.2 17.3±7.1 1.5± 1.2 4.5± 1.6 10/28$ 22/31
DQ3 positive 30 18.3± 12.8 17.0±7.2 1.5± 1.2 4.4± 1.5 9/27 24/3011
DQ3 negative 17 21.1 ±15.5 17.7±9.7 1.4± 1.2 4.8±0.1 1/16 0/17||

Table 3—Laboratory Parameters according to HLA-DQ Status

Group No. of Patients Hemoglobin Level, g/dl* ESR, mm/h* Platelets Per Cubic Millimeter (x 1,000)* RheumatoidFactor

(titer)t

Globulins,g/dl*
DQ1 positive 30 13.4± 1.4 44.9 ±25.1 378 = 109 4.6±2.0$ 1.6±0.45
DQ1 negative 17 13.1± 1.6 43.9±21.9 398 ±124 5.9±1.7$ 2.2±2.1
DQ2 positive 16 13.0± 1.5 41.5±26.8 379 ±127 4.8±2.3 2.2±2.2
DQ2 negative 31 13.5± 1.4 46.1 ±22.3 388 ±109 5.3± 1.8 1.6±0.4
DQ3 positive 30 13.4± 1.5 46.9 ±23.0 405 ±116 5.5± 1.5 1.8± 1.6
DQ3 negative 17 13.2± 1.4 40.3 ±25.1 349 ±103 4.4±2.5 1.7±0.5

/td